World-first trial gives hope to MND sufferers
A recent world-first clinical trial shows there is potential to slow the progression of MND substantially in a proportion of people with the disease.
The clinical trial known as the Lighthouse Project tested the safety and tolerability of an anti-retroviral therapy called Triumeq on forty Australian men with MND. The last patient finished the trial in January this year.
“This will potentially see people with MND lead far more extensive lives once diagnosed”, Professor Dominic Rowe recently told Ray Hadley and listeners of his morning radio show. “Theoretically if we can slow the rate of progression of MND by say 50 per cent we can turn this disease that on average kills people in two to three years, to give them a survival of more like ten to twenty years.”
The trial has involved the repurposing of the drug Triumeq, which is already used to treat HIV infection safely and effectively, to target sporadic MND, which can strike anyone of any age and affects about 90 per cent of MND sufferers.
“It seems we are able to slow MND quite substantially in a proportion of people who have it. So not everyone responds to this medicine but in some people it’s been quite a dramatic therapy. We are excited by these initial results and look forward to sharing more information with you as the trial progresses.”
A second trial, which is testing a novel compound called copper-ATSM to see if it can redress the imbalance of the metals that occur in the brain of MND patients, is also looking promising.
Without the support of generous donors, these trials would not have been possible.
Content owner: Advancement Last updated: 11 Jun 2019 1:52pm